29182-97-6

Basic information

• Product Name: 2-Bromo-N-methylacetanilide
• Synonyms: 2-Bromo-N-methylacetanilide;N-Methyl-2-bromoacetanilide;N-Methyl-N-phenyl-2-bromoacetamide;N-Methyl-N-phenylbromoacetamide;2-Bromo-N-methyl-N-phenylacetamide;2-bromo-N-methyl-N-phenylacetamide(SALTDATA: FREE)
• CAS NO: 29182-97-6
• Molecular Formula: C₉H₁₀BrNO
• Molecular Weight: 228.0858
• Mol File: 29182-97-6.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 277.3 °C at 760 mmHg
• Flash Point: 121.5 °C
• Appearance: /
• Density: 1.478g/cm³
• Vapor Pressure: 0.00455mmHg at 25°C
• Refractive Index: 1.602
• CAS DataBase Reference: 2-Bromo-N-methylacetanilide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-N-methylacetanilide(29182-97-6)
• EPA Substance Registry System: 2-Bromo-N-methylacetanilide(29182-97-6)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• RTECS: AD9650000
• HazardClass: IRRITANT
• Hazardous Substances Data: 29182-97-6(Hazardous Substances Data)

Usage

General Description

2-Bromo-N-methylacetanilide is a chemical compound that is commonly used as an intermediate for the synthesis of various pharmaceuticals. It is obtained by reacting N-methylacetanilide with bromine. The compound is a white to off-white solid, and its chemical formula is C9H10BrNO. It is primarily used as a building block in organic synthesis and medicinal chemistry, and it can also act as a topical analgesic. This chemical has potential applications in the pharmaceutical industry for the development of new drugs and therapeutic agents. However, it is important to handle this compound with care and follow proper safety protocols, as it may pose health hazards if not handled properly.

InChI:InChI=1/C9H10BrNO/c1-11(9(12)7-10)8-5-3-2-4-6-8/h2-6H,7H2,1H3

Upstream product

• 598-21-0 2-Bromoacetyl bromide 
• 100-61-8 N-methylaniline 
• 22118-09-8 2-bromoacetyl chloride 
• 13094-51-4 bromoacetic anhydride 
• 6780-38-7 N-phthaloylglycine chloride 
• 95-51-2 o-chloroaniline 
• 139088-91-8 2-phthalimido-N-(2-chlorophenyl)acetamide 
• 579-10-2 N-acetyl-N-methylaniline 

Downstream Products

• 50508-36-6 N-methyl-N-phenyl-2-(3-nitrophenoxy)acetamide 
• 7797-75-3 2-fluoro-N-methyl-N-phenylacetamide 
• 774198-75-3 C₉H₁₀⁽¹⁸⁾FNO 
• 1196091-50-5 (R)-1-[(Methyl-phenyl-carbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane formate 
• 1337537-42-4 N-methyl-2-(4-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazolo-[3,4-b]quinolin-1-yl)-N-phenylacetamide 
• 1341155-96-1 diethyl (1-diazo-2-(methylphenylamino)-2-oxoethyl)phosphonate 
• 175687-65-7 2-diazo-N-methyl-N-phenyl-2-(phenylsulfonyl)acetamide 
• 93249-33-3 N-methyl-N-phenyl-2-(phenylsulfonyl)acetamide 
• 579-10-2 N-acetyl-N-methylaniline 
• 116433-54-6 2-azido-N-methyl-N-phenylacetamide 

Relevant articles and documents

Modified benzoxazolone derivative as 18-kDa TSPO ligand

We have synthesized six new congeners of acetamidobenzoxazolone for Translocator Protein [18 kDa, TSPO] imaging. The best in vitro binding affinity (10.8?±?1.2?nm) for TSPO was found for N-methyl-2-(5-(naphthalen-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)-N-phen

Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with PotentIn VitroAntiproliferative Activity

Heme oxygenase-1 (HO-1) promotes heme catabolism exercising cytoprotective roles in normal and cancer cells. Herein, we report the design, synthesis, molecular modeling, and biological evaluation of novel HO-1 inhibitors. Specifically, an amide linker in the central spacer and an imidazole were fixed, and the hydrophobic moiety required by the pharmacophore was largely modified. In many tumors, overexpression of HO-1 correlates with poor prognosis and chemoresistance, suggesting the inhibition of HO-1 as a possible antitumor strategy. Accordingly, compounds7iand7l-pemerged for their potency against HO-1 and were investigated for their anticancer activity against prostate (DU145), lung (A549), and glioblastoma (U87MG, A172) cancer cells. The selected compounds showed the best activity toward U87MG cells. Compound7lwas further investigated for its in-cell enzymatic HO-1 activity, expression levels, and effects on cell invasion and vascular endothelial growth factor (VEGF) extracellular release. The obtained data suggest that7lcan reduce cell invasivity acting through modulation of HO-1 expression.

A copper(II)-mediated radical cross-dehydrogenative coupling/sulfinic acid elimination approach to 2-quinolones

A new cyclisation procedure to prepare 4-carboxy-quinolin-2-ones via a one-pot Cu(II)-mediated radical cross-dehydrogenative coupling/sulfinic acid elimination of linear anilides is described. Extensions to more complex substrates are also reported as are